COMMD2

Across TCGA pan-cancer cohorts, COMMD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated COMMD2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher COMMD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated COMMD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and COAD are the cancer types where COMMD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.640	.003	28	view →
UCEC	DFS	Median	II,III,IV	0.466	0.926	.003	22	view →
COAD	DFS	Tertile	IV	0.432	0.916	.038	12	view →
LSCC	DFS	Quartile	All	0.916	1.000	.022	3	view →
GBM	OS	Quartile	All	0.720	0.960	.012	2	view →
PDAC	OS	Tertile	II,III,IV	0.431	0.222	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

COMMD2–CCRCC (OS)

Open the CCRCC breakdown →